Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3774_Библиотеки_им_академика_М_И_Перельмана
.pdf
286
https://t.me/medicina_free
25. Cosford PA, Leng GC, Thomas J. Screening for abdominal aortic aneurysm. Cochrane
Database of Systematic Reviews. 2007:CD002945.
26. Guirguis-Blake JM, Beil TL, Senger CA, Whitlock EP. Ultrasonography screening for
abdominal aortic aneurysms: a systematic evidence review for the U.S.Preventive Services
Task Force. Ann Intern Med. 2014;160:321–9. https://doi.org/10.7326/m13-1844.
27. Johansson M, Zahl PH, Siersma V, Jorgensen KJ, Marklund B, Brodersen J. Benets and
harms of screening men for abdominal aortic aneurysm in Sweden: a registry-based cohort
study. Lancet. 2018;391:2441–7. https://doi.org/10.1016/s0140-6736(18)31031-6.
28. McCaul KA, Lawrence-Brown M, Dickinson JA, Norman PE.Long-term outcomes of the
Western Australian trial of screening for abdominal aortic aneurysms: secondary analysis of
a randomized clinical trial. JAMA Intern Med. 2016;176:1761–7.
jamainternmed.2016.6633.
29. Lawrenson R. Screening for aortic abdominal aneurysm in New Zealand. N Z Med
J. 2012;125:7–9.
30. Sandiford P, Mosquera D, Bramley D.Ethnic inequalities in incidence, survival and mor-
tality from abdominal aortic aneurysm in New Zealand. J Epidemiol Community Health.
2012;66:1097–103. https://doi.org/10.1136/jech-2011-200754.
31. Golledge J, Muller J, Daugherty A, Norman P.Abdominal aortic aneurysm: pathogenesis and
implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605–13. https://doi.
org/10.1161/01.ATV.0000245819.32762.cb.
32. Jones GT, Tromp G, Kuivaniemi H, Gretarsdottir S, Baas AF, Giusti B, etal. Meta-analysis of
genome-wide association studies for abdominal aortic aneurysm identies four new diseasespecic risk loci. Circ Res. 2017;120:341–53. https://doi.org/10.1161/circresaha.116.308765.
33. Krishna SM, Dear AE, Norman PE, Golledge J.Genetic and epigenetic mechanisms and their
possible role in abdominal aortic aneurysm. Atherosclerosis. 2010;212:16–29. https://doi.
org/10.1016/j.atherosclerosis.2010.02.008.
34. Trollope A, Moxon JV, Moran CS, Golledge J.Animal models of abdominal aortic aneu-
rysm and their role in furthering management of human disease. Cardiovasc Pathol.
2011;20:114–23. https://doi.org/10.1016/j.carpath.2010.01.001.
35. Lysgaard Poulsen J, Stubbe J, Lindholt JS.Animal models used to explore abdominal aor-
tic aneurysms: a systematic review. Eur J Vasc Endovasc Surg. 2016;52:487–99. https://doi.
org/10.1016/j.ejvs.2016.07.004.
36. Patelis N, Moris D, Schizas D, Damaskos C, Perrea D, Bakoyiannis C, etal. Animal models
in the research of abdominal aortic aneurysms development. Physiol Res. 2017;66:899–915.
37. Golledge J. Abdominal aortic aneurysm: update on the pathogenesis and medical manage-
ment. Nat Rev Cardiol. 2019;16:225–42.
38. Moran CS, Rush CM, Dougan T, Jose RJ, Biros E, Norman PE, etal. Modulation of kinin B2
receptor signaling controls aortic dilatation and rupture in the angiotensin II-infused apolipoprotein E-decient mouse. Arterioscler Thromb Vasc Biol. 2016;36:898–907.
org/10.1161/atvbaha.115.306945.
39. Moxon JV, Liu D, Moran CS, Crossman DJ, Krishna SM, Yonglitthipagon P, etal. Proteomic
and genomic analyses suggest the association of apolipoprotein C1 with abdominal aortic
aneurysm. Proteomics Clin Appl. 2014;8:762–72. https://doi.org/10.1002/prca.201300119.
40. Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J.Whole genome expression
analysis within the angiotensin II-apolipoprotein E decient mouse model of abdominal aortic aneurysm. BMC Genomics. 2009;10:298.
41. Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H.Whole genome
expression proling reveals a signicant role for immune function in human abdominal aortic
aneurysms. BMC Genomics. 2007;8:237. https://doi.org/10.1186/1471-2164-8-237.
42. Biros E, Gabel G, Moran CS, Schreurs C, Lindeman JH, Walker PJ, etal. Differential gene
expression in human abdominal aortic aneurysm and aortic occlusive disease. Oncotarget.
2015;6:12984–96. https://doi.org/10.18632/oncotarget.3848.
https://doi.org/10.1038/s41569-018-0114-9.
https://doi.org/10.1186/1471-2164-10-298.
J. V. Moxon et al.
https://doi.org/10.1001/
https://doi.

12
https://t.me/medicina_free
Abdominal Aortic Aneurysm Pathology andProgress Towards aMedical Therapy
287
43. Raffort J, Lareyre F, Clement M, Hassen-Khodja R, Chinetti G, Mallat Z.Diabetes and aor-
tic aneurysm: current state of the art. Cardiovasc Res. 2018;114(13):1702–13.
org/10.1093/cvr/cvy174
44. Sweeting MJ, Thompson SG, Brown LC, Powell JT.Meta-analysis of individual patient data
to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J
Surg. 2012;99:655–65. https://doi.org/10.1002/bjs.8707.
45. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: cause, response,
or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075–7.
org/10.1161/atvbaha.110.206573
46. Toghill BJ, Saratzis A, Bown MJ. Abdominal aortic aneurysm-an independent dis-
ease to atherosclerosis? Cardiovasc Pathol. 2017;27:71–5. https://doi.org/10.1016/j.
carpath.2017.01.008.
47. Takagi H, Umemoto T.Association of peripheral artery disease with abdominal aortic aneu-
rysm growth. J Vasc Surg. 2016;64:506–13. https://doi.org/10.1016/j.jvs.2016.01.059.
48. Takagi H, Umemoto T. Associations of coronary and peripheral artery disease with pres-
ence, expansion, and rupture of abdominal aortic aneurysm—a grin without a cat! Vasa.
2017;46:151–8. https://doi.org/10.1024/0301-1526/a000606.
49. Matthews EO, Rowbotham SE, Moxon JV, Jones RE, Vega de Ceniga M, Golledge J.Meta-
analysis of the association between peripheral artery disease and growth of abdominal aortic
aneurysms. Br J Surg. 2017;104:1765–74. https://doi.org/10.1002/bjs.10675.
50. Dua MM, Dalman RL. Hemodynamic inuences on abdominal aortic aneurysm disease:
application of biomechanics to aneurysm pathophysiology. Vasc Pharmacol. 2010;53:11–21.
https://doi.org/10.1016/j.vph.2010.03.004.
51. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT.Abdominal aortic aneu-
rysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16–21.
https://doi.org/10.1161/01.Cir.0000133279.07468.9f.
52. Takagi H, Umemoto T.Coronary artery disease and abdominal aortic aneurysm growth. Vasc
Med. 2016;21:199–208. https://doi.org/10.1177/1358863x15624026.
53. Rahman MN, Khan JA, Mazari FA, Mockford K, McCollum PT, Chetter IC.A randomized
placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress
in patients undergoing elective open repair of abdominal aortic aneurysm. Ann Vasc Surg.
2011;25:32–8. https://doi.org/10.1016/j.avsg.2010.06.006.
54. Moxon JV, Padula MP, Clancy P, Emeto TI, Herbert BR, Norman PE, etal. Proteomic analy-
sis of intra-arterial thrombus secretions reveals a negative association of clusterin and thrombospondin-
org/10.1016/j.atherosclerosis.2011.08.013.
55. Martinez-Pinna R, Madrigal-Matute J, Tarin C, Burillo E, Esteban-Salan M, Pastor-Vargas
C, etal. Proteomic analysis of intraluminal thrombus highlights complement activation in
human abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2013;33:2013–20.
https://doi.org/10.1161/atvbaha.112.301191.
56. Owens AP 3rd, Edwards TL, Antoniak S, Geddings JE, Jahangir E, Wei WQ, etal. Platelet
inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:2032–41. https://doi.org/10.1161/
atvbaha.115.305537
57. Umebayashi R, Uchida HA, Kakio Y, Subramanian V, Daugherty A, Wada J. Cilostazol
attenuates angiotensin II-induced abdominal aortic aneurysms but not atherosclerosis in apolipoprotein E-decient mice. Arterioscler Thromb Vasc Biol. 2018;38:903–12. https://doi.
org/10.1161/atvbaha.117.309707.
58. Moran CS, Seto SW, Krishna SM, Sharma S, Jose RJ, Biros E, etal. Parenteral administration
of factor Xa/IIa inhibitors limits experimental aortic aneurysm and atherosclerosis. Sci Rep.
2017;7:43079. https://doi.org/10.1038/srep43079.
1 with abdominal aortic aneurysm. Atherosclerosis. 2011;219:432–9. https://doi.
.
.
.
https://doi.
https://doi.

288
https://t.me/medicina_free
J. V. Moxon et al.
59. Lu G, Su G, Davis JP, Schaheen B, Downs E, Roy RJ, etal. A novel chronic advanced
stage abdominal aortic aneurysm murine model. J Vasc Surg. 2017;66:232–42.
org/10.1016/j.jvs.2016.07.105
60. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW.Biomarkers of AAA progres-
sion. Part 1: extracellular matrix degeneration. Nat Rev Cardiol. 2009;6:464–74.
org/10.1038/nrcardio.2009.80
61. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW.Biomarkers of abdominal aortic
aneurysm progression. Part 2: inammation. Nat Rev Cardiol. 2009;6:543–52.
org/10.1038/nrcardio.2009.102
62. Golledge J, Tsao PS, Dalman RL, Norman PE.Circulating markers of abdominal aortic aneu-
rysm presence and progression. Circulation. 2008;118:2382–92. https://doi.org/10.1161/
circulationaha.108.802074.
63. Wanhainen A, Mani K, Golledge J. Surrogate markers of abdominal aortic aneurysm
progression. Arterioscler Thromb Vasc Biol. 2016;36:236–44. https://doi.org/10.1161/
atvbaha.115.306538.
64. Sidloff DA, Stather PW, Choke E, Bown MJ, Sayers RD. A systematic review and meta-
analysis of the association between markers of hemostasis and abdominal aortic aneurysm
presence and size. J Vasc Surg. 2014;59:528–35. https://doi.org/10.1016/j.jvs.2013.10.088.
65. Moxon JV, Liu D, Wong G, Weir JM, Behl-Gilhotra R, Bradshaw B, etal. Comparison of
the serum lipidome in patients with abdominal aortic aneurysm and peripheral artery disease.
Circ Cardiovasc Genet. 2014;7:71–9.
66. Golledge J, Kuivaniemi H. Genetics of abdominal aortic aneurysm. Curr Opin Cardiol.
2013;28:290–6. https://doi.org/10.1097/HCO.0b013e32835f0d55.
67. Nicorescu I, Dallinga GM, de Winther MPJ, Stroes ESG, Bahjat M.Potential epigenetic
therapeutics for atherosclerosis treatment. Atherosclerosis. 2019;281:189–97. https://doi.
org/10.1016/j.atherosclerosis.2018.10.006.
68. Khosla S, Morris DR, Moxon JV, Walker PJ, Gasser TC, Golledge J.Meta-analysis of peak
wall stress in ruptured, symptomatic and intact abdominal aortic aneurysms. Br J Surg.
2014;101:1350–7. https://doi.org/10.1002/bjs.9578.
69. Parkinson F, Ferguson S, Lewis P, Williams IM, Twine CP.Rupture rates of untreated large
abdominal aortic aneurysms in patients unt for elective repair. J Vasc Surg. 2015;61:1606–12.
https://doi.org/10.1016/j.jvs.2014.10.023.
70. Lindquist Liljeqvist M, Hultgren R, Siika A, Gasser TC, Roy J. Gender, smoking, body
size, and aneurysm geometry inuence the biomechanical rupture risk of abdominal aortic
aneurysms as estimated by nite element analysis. J Vasc Surg. 2017;65:1014–21.e4. https://
doi.org/10.1016/j.jvs.2016.10.074
71. Drewe CJ, Parker LP, Kelsey LJ, Norman PE, Powell JT, Doyle BJ. Haemodynamics and
stresses in abdominal aortic aneurysms: a uid-structure interaction study into the effect
of proximal neck and iliac bifurcation angle. J Biomech. 2017;60:150–6.
org/10.1016/j.jbiomech.2017.06.029.
72. McGloughlin TM, Doyle BJ. New approaches to abdominal aortic aneurysm rupture
risk assessment: engineering insights with clinical gain. Arterioscler Thromb Vasc Biol.
2010;30:1687–94. https://doi.org/10.1161/atvbaha.110.204529.
73. Conlisk N, Geers AJ, McBride OM, Newby DE, Hoskins PR.Patient-specic modelling of
abdominal aortic aneurysms: the inuence of wall thickness on predicted clinical outcomes.
Med Eng Phys. 2016;38:526–37.
74. Fashandi AZ, Hawkins RB, Salmon MD, Spinosa MD, Montgomery WG, Cullen JM, etal.
A novel reproducible model of aortic aneurysm rupture. Surgery. 2018;163:397–403. https://
doi.org/10.1016/j.surg.2017.10.003.
75. Wang XL, Thompson MM, Dole WP, Dalman RL, Zalewski A.Standardization of outcome
measures in clinical trials of pharmacological treatment for abdominal aortic aneurysm.
Expert Rev Cardiovasc Ther. 2012;10:1251–60. https://doi.org/10.1586/erc.12.128.
.
.
.
https://doi.org/10.1161/circgenetics.113.000343.
.
https://doi.org/10.1016/j.medengphy.2016.03.003.
https://doi.
https://doi.
https://doi.
https://doi.

12
https://t.me/medicina_free
Abdominal Aortic Aneurysm Pathology andProgress Towards aMedical Therapy
289
76. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneu-
rysms. Cochrane Database Syst Rev. 2012:Cd009536.
CD009536.pub2
77. Ricci MA, Slaiby JM, Gadowski GR, Hendley ED, Nichols P, Pilcher DB.Effects of hyper-
tension and propranolol upon aneurysm expansion in the Anidjar/Dobrin aneurysm model.
Ann N Y Acad Sci. 1996;800:89–96.
78. Simpson CF, Kling JM, Palmer RF.Beta-aminopropionitrile-induced dissecting aneurysms
of turkeys: treatment with propranolol. Toxicol Appl Pharmacol. 1970;16:143–53.
79. Slaiby JM, Ricci MA, Gadowski GR, Hendley ED, Pilcher DB.Expansion of aortic aneu-
rysms is reduced by propranolol in a hypertensive rat model. J Vasc Surg. 1994;20:178–83.
80. Boucek RJ, Gunja-Smith Z, Noble NL, Simpson CF.Modulation by propranolol of the lysyl
cross-links in aortic elastin and collagen of the aneurysm-prone turkey. Biochem Pharmacol.
1983;32:275–80.
81. Leach SD, Toole AL, Stern H, DeNatale RW, Tilson MD.Effect of beta-adrenergic blockade
on the growth rate of abdominal aortic aneurysms. Arch Surg. 1988;123:606–9.
82. Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms:
results of a randomized trial. J Vasc Surg. 2002;35:72–9.
83. Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double
blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal
aortic aneurysms. Int Angiol. 1999;18:52–7.
84. Wilmink ABM, Hubbard CSFF, Day NE, Quick CRG.Effect of propanolol on hte expansion
of abdominal aortic aneurysms: a randomised study. Br J Surg. 2000;87:490–516.
85. Golledge J, Norman PE.Current status of medical management for abdominal aortic aneurysm.
Atherosclerosis. 2011;217:57–63. https://doi.org/10.1016/j.atherosclerosis.2011.03.006.
86. Malekzadeh S, Fraga-Silva RA, Trachet B, Montecucco F, Mach F, Stergiopulos N.Role
of the renin-angiotensin system on abdominal aortic aneurysms. Eur J Clin Investig.
2013;43:1328–38. https://doi.org/10.1111/eci.12173.
87. Bicknell CD, Kiru G, Falaschetti E, Powell JT, Poulter NR.An evaluation of the effect of an
angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomized placebo-controlled trial (AARDVARK). Eur Heart J. 2016;37:3213–21.
https://doi.org/10.1093/eurheartj/ehw257.
88. Baxter BT, Terrin MC, Dalman RL. Medical management of small abdominal aortic aneu-
rysms. Circulation. 2008;117:1883–9. https://doi.org/10.1161/circulationaha.107.735274.
89. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-
spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and
abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483–8.
org/10.1161/01.Atv.0000058404.92759.32.
90. Bartoli MA, Parodi FE, Chu J, Pagano MB, Mao D, Baxter BT, et al. Localized admin-
istration of doxycycline suppresses aortic dilatation in an experimental mouse model of
abdominal aortic aneurysm. Ann Vasc Surg. 2006;20:228–36. https://doi.org/10.1007/
s10016-006-9017-z.
91. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R.Clinical trial
of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal
aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells.
Circulation. 2009;119:2209–16.
92. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, etal. Use of doxy-
cycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, doubleblind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606–10. https://doi.org/10.1067/
mva.2001.117891.
93. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW Jr, Kent KC, etal. Prolonged
administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study. J Vasc Surg. 2002;36:1–12.
.
https://doi.org/10.1161/circulationaha.108.806505.
https://doi.org/10.1002/14651858.
https://doi.

290
https://t.me/medicina_free
94. Meijer CA, Stijnen T, Wasser MN, Hamming JF, van Bockel JH, Lindeman JH.Doxycycline
for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med.
2013;159:815–23. https://doi.org/10.7326/0003-4819-159-12-201312170-00007.
95. Tsuruda T, Kato J, Hatakeyama K, Kojima K, Yano M, Yano Y, etal. Adventitial mast cells
contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res.
2008;102:1368–77. https://doi.org/10.1161/circresaha.108.173682.
96. Sun J, Zhang J, Lindholt JS, Sukhova GK, Liu J, He A, etal. Critical role of mast cell chy-
mase in mouse abdominal aortic aneurysm formation. Circulation. 2009;120:973–82.
doi.org/10.1161/circulationaha.109.849679
97. Sillesen H, Eldrup N, Hultgren R, Lindeman J, Bredahl K, Thompson M, etal. Randomized
clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm. Br J Surg. 2015;102:894–901. https://doi.org/10.1002/bjs.9824.
98. Krishna SM, Seto SW, Moxon JV, Rush C, Walker PJ, Norman PE, etal. Fenobrate increases
high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal
aortic aneurysm progression in a mouse model. Am J Pathol. 2012;181:706–18. https://doi.
org/10.1016/j.ajpath.2012.04.015.
99. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, etal. Peroxisome proliferator-
activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
Atherosclerosis. 2010;210:51–6. https://doi.org/10.1016/j.atherosclerosis.2009.10.027.
100. Pinchbeck JL, Moxon JV, Rowbotham SE, Bourke M, Lazzaroni S, Morton SK, et al.
Randomized placebo-controlled trial assessing the effect of 24-week fenobrate therapy on
circulating markers of abdominal aortic aneurysm: outcomes from the FAME2 trial. J Am
Heart Assoc. 2018;7:e009866.
101. Rowbotham SE, Bourke B, Bourke M, Jaeggi R, Jenkins J, Moxon JV, etal. Fenobrate in the
management of AbdoMinal aortic aneurysm (FAME)-2: the study protocol for a randomized,
placebo-controlled trial. Int J Clin Trials. 2016;3:217–24.
102. Rowbotham SE, Cavaye D, Jaeggi R, Jenkins JS, Moran CS, Moxon JV, etal. Fenobrate in
the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised
controlled trial. Trials. 2017;18:1. https://doi.org/10.1186/s13063-016-1752-z.
103. Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, etal. Statins reduces
abdominal aortic aneurysm growth, rupture and perioperative mortality: a systematic
review and meta-analysis. J Am Heart Assoc. 2018;7:e008657. https://doi.org/10.1161/
JAHA.118.008657.
104. Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham M, et al. Management of
abdominal aortic aneurysms clinical practice guidelines of the European society for
surgery. Eur J Vasc Endovasc Surg. 2011;41(Suppl 1):S1–s58.
ejvs.2010.09.011.
105. Baxter BT, Matsumura J, Curci J, McBride R, Blackwelder WC, Liu X, etal. Non-invasive
treatment of abdominal aortic aneurysm clinical trial (N-TA(3)CT): design of a phase IIb,
placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction
of growth of small abdominal aortic aneurysm. Contemp Clin Trials. 2016;48:91–8. https://
doi.org/10.1016/j.cct.2016.03.008.
106. Dattani N, Sayers RD, Bown MJ.Diabetes mellitus and abdominal aortic aneurysms: a review
of the mechanisms underlying the negative relationship. Diab Vasc Dis Res. 2018;15:367–74.
https://doi.org/10.1177/1479164118780799.
107. Hsu CY, Su YW, Chen YT, Tsai SH, Chang CC, Li SY, etal. Association between use of oral-
antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis. Cardiovasc
Diabetol. 2016;15:125. https://doi.org/10.1186/s12933-016-0447-9.
108. Itoga NK, Rothenberg KA, Suarez P, Ho TV, Mell MW, Xu B, etal. Metformin prescription
status and abdominal aortic aneurysm disease progression in the U.S. veteran population. J
Vasc Surg. 2019;69(3):710–716.e3. https://doi.org/10.1016/j.jvs.2018.06.194.
109. Golledge J, Morris DR, Pinchbeck J, Rowbotham S, Jenkins J, Bourke M, etal. Metformin
prescription is associated with a reduction in the combined incidence of surgical repair and
https://doi.org/10.1161/JAHA.118.009866.
.
J. V. Moxon et al.
https://
vascular
https://doi.org/10.1016/j.

12 Abdominal Aortic Aneurysm Pathology andProgress Towards aMedical Therapy
https://t.me/medicina_free
291
rupture related mortality in patients with abdominal aortic aneurysm. Eur J Vasc Endovasc
Surg. 2019;57(1):94–101.
110. Golledge J, Moxon J, Pinchbeck J, Anderson G, Rowbotham S, Jenkins J, etal. Association
between metformin prescription and growth rates of abdominal aortic aneurysms. Br J Surg.
2017;104:1486–93. https://doi.org/10.1002/bjs.10587.
111. Fujimura N, Xiong J, Kettler EB, Xuan H, Glover KJ, Mell MW, etal. Metformin treatment
status and abdominal aortic aneurysm disease progression. J Vasc Surg. 2016;64:46–54.e8.
https://doi.org/10.1016/j.jvs.2016.02.020.
112. Yang L, Shen L, Gao P, Li G, He Y, Wang M, etal. Effect of AMPK signal pathway on
pathogenesis of abdominal aortic aneurysms. Oncotarget. 2017;8:92827–40.
org/10.18632/oncotarget.21608.
113. Hinchliffe RJ. Metformin and abdominal aortic aneurysm. Eur J Vasc Endovasc Surg.
2017;54:679–80. https://doi.org/10.1016/j.ejvs.2017.08.016.
114. Ford MD, Black AT, Cao RY, Funk CD, Piomelli U.Hemodynamics of the mouse abdominal
aortic aneurysm. J Biomech Eng. 2011;133:121008. https://doi.org/10.1115/1.4005477.
115. Phillips EH, Di Achille P, Bersi MR, Humphrey JD, Goergen CJ.Multi-modality imaging
enables detailed hemodynamic simulations in dissecting aneurysms in mice. IEEE Trans Med
Imaging. 2017;36:1297–305. https://doi.org/10.1109/tmi.2017.2664799.
116. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience
research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol.
2010;8:e1000412.
117. Morris DR, Cunningham MA, Ahimastos AA, Kingwell BA, Pappas E, Bourke M, et al.
TElmisartan in the management of abDominal aortic aneurYsm (TEDY): The study protocol
for a randomized controlled trial. Trials. 2015;16:274.
https://doi.org/10.1016/j.ejvs.2018.07.035.
https://doi.
https://doi.org/10.1371/journal.pbio.1000412.

Chapter 13
https://t.me/medicina_free
Pathophysiology andPrinciples
ofManagement ofHereditary Aneurysmal
Aortopathies
MèlanieH.A.M.Perik, AlineVerstraeten, andBartL.Loeys
Key Learning Points
An aortic aneurysm is a progressive dilatation of the aorta which entails a sub-
•
stantial risk for aortic rupture or dissection, i.e. events that come with an ultimate
mortality rate of 80%.
•
TAAs can be subdivided in syndromic forms, such as Marfan syndrome or
Loeys-Dietz syndrome, and non-syndromic forms based on the presence or
absence of multi-systemic manifestations, respectively.
• Roughly 30 TAA genes have been identied to date, explaining about 30% of all
TAA probands. TAA genes encode proteins involved in ECM homeostasis, the
TGF-β pathway or the VSMC contractile apparatus.
• Early clinical and/or molecular diagnosis and serial cardiovascular follow-up
with either CT, TTE, TEE or MRI are important actions in TAA management.
• The molecular TAA landscape facilitates gene-tailored therapy. For instance, in
case of SMAD2, SMAD3, TGFBR1, TGBFBR2 mutations, surgical intervention
should already be considered for aortic diameters as small as 4.0–4.5cm.
Pharmacological TAA treatment usually encompasses β-blocker or losartan
•
administration.
13.1 Introduction
Aortic aneurysms result from structural weakening of the aortic wall [1], and predispose to aortic rupture and dissection because of a progressive increase in wall
tension. Only 5% of patients experience warning symptoms prior to aortic rupture
M. H. A. M. Perik · A. Verstraeten · B. L. Loeys (*)
Cardiogenetics, Center for Medical Genetics, University of Antwerp/Antwerp University
Hospital, Antwerp, Belgium
e-mail: bart.loeys@uantwerpen.be
R. Fitridge (ed.), Mechanisms of Vascular Disease,
https://doi.org/10.1007/978-3-030-43683-4_13
293© Springer Nature Switzerland AG 2020

294
https://t.me/medicina_free
or dissection, which are estimated to be responsible for 1–2% of all deaths in industrialized countries [1, 2]. Due to the silent and unpredictable disease course of aneurysmal disease, mortality rates are likely to be underestimated [2].
Based on the anatomic location, aortic aneurysms can be divided in two groups:
abdominal aortic aneurysms (AAAs) and thoracic aortic aneurysms (TAAs). AAA
is the most common form, in which the aneurysm is located below the diaphragm.
A positive family history is present in 12% of cases, suggesting a role for genetics
in the aetiology of AAA.Monogenic AAA causes remain to be identied, but
multiple AAA risk genes have been reported including: DAB2IP, LRP1,
CDKN2B-AS1, CNTN3, LPA , IL6R, SORT1, MMP3, AGTR1, ACE, APOA1,
PEPD, CD22 and MTHFR [3]. Age, gender (males > females), European ancestry,
hypertension, smoking and/or diabetes, however, also impinge signicantly on
AAA risk [4].
TAAs, located above the diaphragm, occur less frequently than AAAs but have
been more extensively investigated due to a higher heritability and a younger age at
onset. In approximately 20% of TAA patients, a positive family history is identied
and in about 30% of these, a mutation is found in one of the roughly 30 currently
known TAA genes (Table13.1). Patients with thoracic aortic aneurysm and dissection (TAAD) often do not present with other risk factors such as hypertension.
TAAD, which is clinically characterized by excruciating pain of sudden onset,
can also be classied in two groups based on their anatomic location; type A dissections which affect the proximal aorta and the aortic arch on one hand, and type B
dissections which begin beyond the subclavian artery on the other hand. Type A
dissections are associated with the most serious complications. Since the aetiology
of TAA has been more extensively studied from a genetic perspective, TAA will be
the main focus of this book chapter.
M. H. A. M. Perik et al.
13.2 Epidemiology
It is not straightforward to accurately determine the prevalence of TAA(D) as many
patients remain asymptomatic, and hence undiagnosed, until aortic dissection or
rupture occurs. The current TAAD incidence is estimated to be 2.7/100,000 personyears, but most probably the true gure is higher [5]. In general, males are more
frequently affected than women. However, mortality rates are higher for female
patients which is thought to be due to atypical clinical presentation leading to diagnostic delay [6]. TAAD is associated with high morbidity and mortality. Dissection/
rupture has been shown to occur in about 37% of TAA patients [7], of which about
40% die immediately. Each hour after the initial event another 1% of the patients die
if surgical intervention is not performed and an additional 5% die during and 20%
shortly after emergency intervention [8]. Preventive surgical intervention reduces
the mortality rate down to less than 5%, emphasizing the importance of serial cardiovascular monitoring of TAA patients [9].

13
https://t.me/medicina_free
Pathophysiology andPrinciples ofManagement ofHereditary Aneurysmal…
295
Table 13.1
genotype. OMIM; Online Mendelian Inheritance in Man
Disease Gene Inheritance Cardiovascular features OMIM Ref.
Syndromic TAA disorders
Marfan syndrome FBN1 AD TAA(D), mitral valve disease 154700 [
Loeys-Dietz syndrome
type 1
Loeys-Dietz syndrome
type 2
Loeys-Dietz syndrome
type 3
Loey-Dietz syndrome
type 4
Loeys-Dietz syndrome
type 5
Loeys-Dietz syndrome
type 6
Shprintzen-Goldberg
syndrome
Meester-Loeys
syndrome
Vascular Ehlers-Danlos
syndrome
Vascular like Ehlers-
Danlos syndrome
Classical Ehlers-Danlos
syndrome
Periventricular nodular
heterotopia type 1
Arterial tortuosity
syndrome
Cutis laxa ELN AD Occasionally TAA, mitral
Cutis laxa type 1 EFEMP2 AR Arterial tortuosity, aortic
Non-syndromic TAA disorders
Familial thoracic aortic
aneurysm 6
Familial thoracic aortic
aneurysm 4
Familial thoracic aortic
aneurysm 7
Familial thoracic aortic
aneurysm 8
NA MAT2A AD TAA(D), BAV NA [58]
Familial thoracic aortic
aneurysm 11
Thoracic aortic aneurysm and dissection related disorders with their respective
TGFBR1 AD TAA(D), arterial tortuosity,
TGFBR2 AD TAA(D), arterial tortuosity,
SMAD3 AD TAA(D), arterial tortuosity,
TGFB2 AD TAA(D), arterial tortuosity,
TGFB3 AD TAA(D), mitral valve disease 615582 [
SMAD2 AD TAA(D) NA [
SKI AD TAA(D) 182212 [
BGN X-linked TAA(D) 300989 [
COL3A1 AD TAA(D), arterial aneurysms 130050 [
COL1A1 AD TAA(D), arterial aneurysms 130060 [44]
COL5A1 AD TAA(D), arterial aneurysms 130000 [
FLNA X-linked TAA(D), mitral valve disease 300537 [
SLC2A10 AR Arterial tortuosity and
ACTA2 AD Livedo reticularis, iris
MYH11 AD PDA, TAA(D) 132900 [55]
MYLK AD TAA(D) 613780 [56]
PRKG1 AD TAA(D), arterial tortuosity,
FOXE3 AD TAA(D) 617349 [59]
arterial aneurysms
arterial aneurysms
arterial aneurysms
mitral valve disease
aneurysms
and aortic valve regurgitation
aneurysms, stenosis
occuli, Moya-Moya disease
hypertension
609192 [
610168 [
613795 [
614437 [
46]
208050 [20]
123700 [47]
614437 [51]
611788 [53,
54]
615436 [57]
(continued)
24]
31]
31]
31]
33]
34]
32]
37]
39]
42]
43]
45,

296
M. H. A. M. Perik et al.
https://t.me/medicina_free
Table 13.1 (continued)
Disease Gene Inheritance Cardiovascular features OMIM Ref.
Aortic valve disease NOTCH1 AD TAA(D), BAV 109730 [
Familial thoracic aortic
aneurysm 9
Aortic valve disease 2 SMAD6 AD TAA(D), BAV 614823 [
Aortic valve disease 3 ROBO4 AD TAA(D), BAV, aortic valve
Familial thoracic aortic
aneurysm 10
MFAP5 AD Paroxysmal atrial brillation,
TAA(D)
regurgitation/stenosis
LOX AD Aortic root aneurysm, BAV,
TAA(D)
61]
616166 [
607528 [
617168 [
61]
62]
63]
64]
13.3 Pathophysiology
Aortic aneurysms are pathological dilatations of the aorta, caused by vascular wall
weakness. The aortic wall consists of three different layers: the intima, the media
and the adventitia. The innermost layer, i.e. the intima, is composed of a metabolically important endothelial monolayer that is supported by internal elastic laminae.
This sub-endothelial elastic matrix harmonizes the motion of the intima and media
during cyclic aortic expansion or contraction [10, 11]. The media makes up the largest part of the vessel wall and consists of vascular smooth muscle cells (VSMCs)
embedded in extracellular matrix (ECM) proteins such as elastins, collagens and
proteoglycans. The ECM provides elasticity and tensile strength, besides sequestering a variety of growth factors. ECM homeostasis is controlled by matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs (TIMPS) produced by synthetic
VSMCs during vascular remodelling. Whereas MMPs degrade the ECM, TIMPs
reduce ECM degradation through MMP inhibition [12]. Contractile VSMCs control
the vessel’s luminal diameter, and hence blood pressure, by mediating vessel contraction or relaxation. The adventitia is the outer layer of the vessel wall and consists
of collagen and elastin bres as well as broblasts, immunomodulatory cells, vasa
vasorum endothelial cells and pericytes. It contributes to aortic integrity and provides nutritional circulation to the vascular wall [10, 11].
In TAA patients, a shift from contractile VSMCs towards synthetic VSMCs has
been observed leading to an imbalance between MMP and TIMP expression.
Pathological amounts of MMPs are secreted, resulting in disproportionate ECM
degradation [13], ECM disorganisation and growth factor release [14]. Moreover,
loss of VSMC contractility reduces the aortic wall’s capacity to properly control the
luminal diameter. In addition to a shift in VSMC function, excessive VSMC apoptosis (see Glossary) is typically observed. In the VSMC-depleted regions, degradation
products of proteoglycans and glycosaminoglycans as well as inammatory cells
can be found [15, 16]. Collectively, these events are hallmarks of a phenomenon
called medial degeneration, which weakens the aortic wall and contributes to aortic
aneurysm formation and progression according to Laplace’s Law: circumferential
wall tension=transmural pressure x vessel radius. Ruptures or dissections occur
when the mechanical stress on the vascular wall overpowers the tissue strength [17].
Соседние файлы в папке Библиотека им академика М.И. Перельмана
